FinnCap restated their corporate rating on shares of Synairgen (LON:SNG) in a research note published on Wednesday morning, Stock Target Advisor reports.

Shares of LON SNG traded up GBX 16.80 ($0.22) during midday trading on Wednesday, reaching GBX 49 ($0.64). 6,881,284 shares of the company were exchanged, compared to its average volume of 78,152. Synairgen has a 1 year low of GBX 5.50 ($0.07) and a 1 year high of GBX 30.33 ($0.40). The stock has a fifty day simple moving average of GBX 17.30 and a 200 day simple moving average of GBX 10.29. The stock has a market cap of $53.62 million and a P/E ratio of -14.41.

Synairgen Company Profile

Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Further Reading: How Buying a Call Option Works

Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.